About Melanotan Compound

Who we are

Melanotan Compound is an independent editorial project that publishes summaries of the peer-reviewed research literature on Melanotan 2. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "compound" in our name is editorial framing — a position we occupy relative to the literature, reading Melanotan 2 as one chemical compound in a family of melanocortin peptides. It is not a claim that this site compounds, supplies, or dispenses anything. It does not.

Our editorial angle

Most writing about Melanotan 2 treats it in isolation. We read it in context — alongside its relatives afamelanotide (Melanotan I) and bremelanotide (PT-141) — because the comparison is what makes the parent compound legible. One scaffold produced an approved photoprotection drug, an approved sexual-function drug, and an unapproved tanning peptide, and the differences between them are the most informative thing in the field.

We lead with what the studies measured and we attribute every quantitative claim to a named source. Where the evidence is strong — the pigmentation mechanism, the small human studies — we say so plainly. Where it is thin or absent — long-term safety, large trials — we say that just as plainly.

How we handle the evidence

We separate three things and never let them blur: cited clinical and preclinical findings; clearly labeled community reports (anecdote, not evidence); and documented safety case reports. We do not provide dosing, we do not tell anyone to use Melanotan 2, and we note throughout that it is not approved for human use by any regulator. Our citations are listed in full on the Melanotan 2 references page, each linked to PubMed, so any reader can check our reading against the primary literature.